How PI Health Sciences Delivers Real-Time Visibility and Scientific Accountability

About this episode

Alessio Piccoli discusses the importance of control in CDMO selection and how PI Health Sciences is redefining scientific accountability and digital execution.

“The right CDMO is not the one with the biggest plant or the lowest price. It’s the one with the judgment, the systems, and the incentives to protect your molecule when complexity, scale, and scrutiny converge.” Alessio Piccoli , Chief Commercial Officer at PI Health Sciences (PIHS), a CDMO and CRO with discovery and process R&D capabilities in Jaipur and Hyderabad, India, and EU cGMP manufacturing in Lodi, Italy – a site holding FDA, AIFA, and KFDA approvals. The organization is backed by PI Industries, a global life sciences powerhouse with over 80 years of legacy in turning complex science into scalable real-world outcomes. In this episode of the PharmaSource podcast, Alessio explains why the most consequential differentiator in CDMO selection is control. He shares how PIHS is building a model defined by scientific accountability, digital execution, and a partnership mindset that links development decisions to commercial reality. Read more .

People in this episode

Guest: Alessio Piccoli

Topics covered

• CDMO selection
• scientific accountability
• digital execution
• partnership mindset
• real-time visibility
• life sciences

Keywords

• CDMO
• CRO
• scientific accountability
• real-time visibility
• life sciences
• digital execution
• partnership

Mentioned in this episode

Organizations: PI Health Sciences, PI Industries, FDA, AIFA, KFDA

Places: Jaipur, Hyderabad, Lodi

More episodes of PharmaSource Podcast

• How Sanofi Navigates Regulatory CMC Across Global Markets: Insights from Manda Pasarkar · June 11, 2026 · 31 min
• The Politics Behind the Pipeline: How MFN Pricing and Tariffs Are Reshaping Pharma's Global Strategy · June 8, 2026 · 18 min
• How to Build a Resilient Global Vaccine Supply Chain: From Crisis to Capability · June 4, 2026 · 46 min
• How Lonza Is Outgrowing the CDMO Market with Bioconjugation, AI, and Regionalization · May 31, 2026 · 29 min
• The Strategic Partnership Gap: Why CDMOs Are Meeting Pharma's Expectations Less Than Half the Time with Simon-Kucher · May 27, 2026 · 26 min
• Creative Financing Strategies for Biotech's Bear Market, Beyond the VC Round · May 25, 2026 · 29 min